Aktis Oncology Upsizes IPO Targeting $945.4 Million Valuation
Aktis Oncology, a Boston-based cancer drug developer, announced an upsized IPO aiming to raise $317.7 million. The company plans to sell 17.65 million shares at $16-$18 each, marking the first U.S. IPO of 2026. Eli Lilly has committed to a $100 million share purchase.
洞察:
Aktis Oncology, a Boston-based cancer drug developer, has announced an upsized initial public offering (IPO) targeting a valuation of up to $945.4 million. The company aims to raise as much as $317.7 million through the sale of 17.65 million shares, priced between $16 and $18 per share. The offering marks the first U.S. IPO of 2026, highlighting a strong start to the year for the biotech sector.
